Growth Hormone Suppression Test at Chughtai Lab

Growth Hormone Suppression Test (with Glucose Challenge) at Chughtai Lab

The Growth Hormone Suppression Test (with Glucose Challenge) is the gold-standard dynamic endocrine investigation used to diagnose states of growth hormone (GH) excess, primarily acromegaly in adults and gigantism in pediatric patients. Growth hormone, or somatotropin, is synthesized and secreted by the somatotroph cells of the anterior pituitary gland in a highly pulsatile and episodic manner. Because of this physiological fluctuation, a single random measurement of serum GH is clinically unreliable and cannot be used to rule out or confirm a diagnosis of hypersecretion. To overcome this limitation, dynamic endocrine testing is employed. The oral glucose tolerance test (OGTT) serves as the primary suppression test. In healthy individuals, the ingestion of a concentrated glucose load induces hyperglycemia, which triggers a physiological feedback loop: the hypothalamus increases somatostatin release and decreases growth hormone-releasing hormone (GHRH) secretion, thereby suppressing GH release from the anterior pituitary to extremely low or undetectable levels. Conversely, in patients with autonomous, unregulated GH secretion—most commonly due to a benign pituitary somatotroph adenoma—this physiological suppression mechanism fails.

Chughtai Lab, a premier diagnostic institution in Pakistan, offers this specialized dynamic endocrine investigation with the highest degree of analytical precision. Utilizing advanced chemiluminescent immunoassay (CLIA) technology, Chughtai Lab ensures accurate quantification of serum GH levels at precise intervals, providing clinical endocrinologists with the robust data required to establish a definitive diagnosis, plan transsphenoidal neurosurgery, or monitor therapeutic response. The test evaluates the integrity of the hypothalamic-pituitary-somatotropic axis, offering unparalleled diagnostic value. By measuring both glucose and GH levels sequentially, clinicians can assess not only the secretory autonomy of the pituitary gland but also the patient’s metabolic response to a high carbohydrate load, which is critical given the high prevalence of secondary diabetes mellitus in patients with growth hormone excess.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is vital to ensure the clinical validity of the Growth Hormone Suppression Test, as physical stress, nutritional status, and metabolic factors can significantly influence growth hormone secretion. Patients must adhere to the following guidelines:

• Strict Overnight Fasting: The patient must fast for 8 to 12 hours before the procedure. Only plain water is permitted during this period. Food, tea, coffee, and other beverages must be avoided.
• Medication Review: Patients must inform their physician and the laboratory staff of all medications, supplements, and hormonal therapies they are currently taking. Certain drugs, such as glucocorticoids, estrogens, somatostatin analogs, and diabetes medications, may interfere with the test results and may need to be temporarily held under medical supervision.
• Physical Activity Restriction: Strenuous physical exercise must be avoided for at least 24 hours prior to the test, as physical exertion is a potent physiological stimulator of growth hormone release.
• Stress Reduction and Rest: Upon arriving at Chughtai Lab, the patient should rest quietly for 30 minutes before the first blood draw. Emotional or physical stress can cause transient spikes in GH levels, leading to false-positive or ambiguous results.
• Avoid Smoking and Caffeine: Smoking and caffeine consumption are strictly prohibited on the morning of the test, as they can alter glucose metabolism and growth hormone dynamics.

During the Procedure

The Growth Hormone Suppression Test is a multi-step dynamic investigation performed by experienced phlebotomists at Chughtai Lab. The procedure follows a standardized clinical protocol:

• Intravenous Cannulation: To avoid the stress of repeated venipunctures—which can artificially elevate growth hormone levels—an indwelling intravenous (IV) cannula is inserted into a forearm vein. The patient is advised to remain seated or semi-recumbent throughout the test.
• Baseline Blood Draw (Time 0): After a brief rest period to allow any insertion-related stress to subside, the first blood sample is drawn to measure baseline serum growth hormone and plasma glucose levels.
• Glucose Ingestion: The patient is then asked to drink a standardized oral glucose solution. For adults, this typically consists of 75 grams of anhydrous glucose dissolved in approximately 250–300 ml of water. For pediatric patients, the dose is calculated based on body weight (1.75 grams per kilogram, up to a maximum of 75 grams). The solution must be consumed entirely within 5 minutes.
• Serial Blood Sampling: Following glucose ingestion, blood samples are drawn through the IV cannula at precise intervals. The standard protocol requires sampling at 30, 60, 90, and 120 minutes. At each interval, both growth hormone and glucose levels are measured.
• Patient Monitoring: The patient is closely monitored throughout the 2-hour period for any signs of nausea, dizziness, or vasovagal reactions, which can occasionally occur after consuming a concentrated glucose solution.
• Post-Procedure Care: Once the final blood sample is collected at the 120-minute mark, the IV cannula is safely removed, and a light snack may be consumed. The patient can immediately resume normal daily activities.

When is a Growth Hormone Suppression Test Performed?

Diagnosis of Acromegaly in Adult Patients

Physicians request this test when an adult patient exhibits classic clinical features of acromegaly, a rare chronic disorder characterized by excessive growth hormone production after the epiphyseal plates have fused. Clinical symptoms include progressive enlargement of the hands and feet (manifested by changes in ring or shoe size), coarse facial features, frontal bossing, mandibular prognathism, macroglossia, excessive sweating, sleep apnea, and carpal tunnel syndrome. The test is critical to confirm autonomous GH secretion, which is almost always caused by a benign pituitary somatotroph adenoma.

Evaluation of Pituitary Somatotroph Adenomas

When a brain MRI reveals a pituitary mass (either a microadenoma or a macroadenoma), the Growth Hormone Suppression Test is performed to determine if the tumor is biochemically active. Pituitary adenomas can be non-functioning or secretory. Identifying whether a tumor is actively secreting growth hormone is essential for determining the appropriate therapeutic pathway, whether it involves neurosurgical resection, medical management, or stereotactic radiotherapy.

Investigation of Pediatric Gigantism

In children and adolescents whose epiphyseal plates have not yet fused, chronic growth hormone excess leads to pituitary gigantism. Pediatricians request this test when a child exhibits rapid, excessive linear growth that deviates significantly from their established growth curve, accompanied by joint pain, delayed puberty, coarse facial features, and cardiomegaly. The test helps distinguish pathological gigantism from constitutional tall stature or familial rapid growth.

Post-Surgical and Therapeutic Monitoring

Following transsphenoidal neurosurgery to remove a GH-secreting pituitary tumor, the Growth Hormone Suppression Test is performed to assess the success of the intervention. It is typically scheduled 3 to 6 months post-operatively. A normal suppression response indicates complete biochemical remission, whereas a failure to suppress indicates residual tumor tissue, necessitating adjuvant therapies such as somatostatin analogs, dopamine agonists, GH receptor antagonists, or radiotherapy.

Clarification of Discordant IGF-1 and Random GH Levels

Insulin-like Growth Factor 1 (IGF-1) is the primary screening tool for growth hormone excess because of its stable circulating levels. However, cases arise where a patient has borderline elevated IGF-1 levels but normal or ambiguous random GH levels, or vice versa. The Growth Hormone Suppression Test is employed as the definitive diagnostic tie-breaker to confirm or rule out pathological GH hypersecretion in these clinically ambiguous scenarios.

What Does a Growth Hormone Suppression Test Detect?

The Growth Hormone Suppression Test provides a comprehensive biochemical profile of the somatotropic axis and glucose metabolism. It specifically detects:

• Normal Physiological Suppression: In healthy individuals, serum growth hormone levels suppress to less than 1.0 mcg/L (and often less than 0.3 mcg/L with highly sensitive modern assays) at any point during the 2-hour post-glucose challenge.
• Autonomous Growth Hormone Secretion: A failure of serum GH to suppress below 1.0 mcg/L (or the laboratory’s specific highly sensitive threshold) confirms the diagnosis of acromegaly or gigantism.
• Paradoxical Growth Hormone Rise: In some patients with somatotroph adenomas, glucose ingestion paradoxically causes an increase in GH levels rather than suppression, a highly specific diagnostic finding.
• Baseline Hyperglycemia: Elevated fasting glucose levels, which may indicate pre-existing impaired fasting glucose or undiagnosed diabetes mellitus.
• Impaired Glucose Tolerance: Abnormal post-challenge glucose levels that do not return to normal limits within 120 minutes, reflecting insulin resistance.
• Secondary Diabetes Mellitus: Overt diabetes induced by the chronic counter-regulatory effects of excess growth hormone, which impairs peripheral glucose uptake and increases hepatic gluconeogenesis.
• Somatotroph Microadenoma Activity: Unregulated hormone release from small pituitary tumors (less than 10 mm in diameter).
• Somatotroph Macroadenoma Activity: High-volume hormone secretion from larger pituitary tumors (greater than 10 mm in diameter), often associated with very high baseline GH levels.
• Ectopic GHRH Secretion: Rare neuroendocrine tumors (e.g., bronchial or pancreatic carcinoids) that secrete GHRH, causing secondary pituitary somatotroph hyperplasia and GH excess.
• Ectopic Growth Hormone Secretion: Extremely rare non-pituitary tumors that directly secrete growth hormone.
• Mixed Pituitary Adenomas: Tumors that co-secrete growth hormone and other anterior pituitary hormones, most commonly prolactin.
• Pituitary Stalk Compression: Mild elevations in prolactin due to tumor mass effect on the pituitary stalk, disrupting normal hypothalamic dopamine inhibition.
• Hypopituitarism: Concomitant deficiencies in other pituitary hormones (such as ACTH, TSH, LH, or FSH) caused by tumor compression of normal pituitary tissue.
• Complete Biochemical Remission: Normalization of the GH suppression response following successful surgical resection of a pituitary tumor.
• Partial Biochemical Response: Incomplete suppression of GH post-surgery or during medical therapy, indicating the presence of residual active tumor tissue.
• Treatment Failure: Persistent, unsuppressed GH levels following surgical, medical, or radiation therapy, indicating the need for alternative treatment modalities.
• Disease Recurrence: Loss of previously documented GH suppression during long-term follow-up, signaling tumor recurrence.
• Pegvisomant Therapy Efficacy: Monitoring metabolic parameters, though direct GH levels may remain elevated due to assay cross-reactivity with this GH receptor antagonist.
• Somatostatin Analog Efficacy: Assessment of the suppressive effect of drugs like octreotide or lanreotide on autonomous GH secretion.
• Radiation-Induced Hypopituitarism: Gradual decline in pituitary hormone reserve over years following cranial radiotherapy for a pituitary tumor.
• Stress-Induced GH Elevation: Transient, non-pathological spikes in baseline GH that normalize during subsequent serial draws, highlighting the importance of the indwelling cannula.
• Estrogen-Induced GH Resistance: Elevated baseline GH levels with normal IGF-1 levels in women taking oral estrogens, which is clarified by the dynamic suppression test.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is dedicated to providing prompt, accurate, and reliable diagnostic reports. Because the Growth Hormone Suppression Test involves multiple serial blood samples and specialized chemiluminescent immunoassay (CLIA) testing, the turnaround time is typically 24 to 48 hours from the time of sample collection. This allows our clinical pathologists to perform rigorous quality control checks and correlate the serial GH and glucose measurements. Patients are notified via SMS as soon as their reports are finalized. Reports can be accessed and downloaded online through the official Chughtai Lab website or the user-friendly Chughtai Healthcare mobile application. Hard copies of the report can also be collected from any Chughtai Lab collection center across Pakistan or delivered directly to the patient’s home through our dedicated courier service.

Growth Hormone Suppression Test Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Baseline Growth Hormone (GH)	Variable (typically < 5.0 mcg/L, but highly pulsatile)	Markedly elevated in active acromegaly; occasionally normal due to pulsatile nature.
Post-Glucose GH (60, 90, 120 mins)	Suppression to < 1.0 mcg/L (often < 0.3 mcg/L with sensitive assays)	Failure to suppress (> 1.0 mcg/L), or paradoxical rise in GH, indicating autonomous secretion.
Baseline Plasma Glucose	70 – 100 mg/dL (Fasting)	> 100 mg/dL (Impaired Fasting Glucose) or > 126 mg/dL (Diabetes Mellitus).
2-Hour Post-Glucose Plasma Glucose	< 140 mg/dL	140 – 199 mg/dL (Impaired Glucose Tolerance) or > 200 mg/dL (Diabetes Mellitus).
Serum IGF-1 (Correlation)	Within age- and sex-specific reference ranges	Elevated, supporting the diagnosis of chronic growth hormone excess.
Pituitary Gland (Anatomy via MRI)	Normal size and structure of the anterior pituitary	Presence of microadenoma (<10 mm) or macroadenoma (>10 mm) with sellar expansion.
Other Anterior Pituitary Hormones	Normal levels of TSH, ACTH, LH, FSH, and Prolactin	Deficiencies (hypopituitarism) or elevated Prolactin due to co-secretion or stalk compression.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Growth Hormone Suppression Test?

• Experienced Healthcare Professionals: Our team of highly qualified clinical pathologists, biochemists, and lab technologists ensures the highest standards of diagnostic accuracy.
• CAP Accredited Laboratory: Chughtai Lab is accredited by the College of American Pathologists (CAP), reflecting our commitment to international quality standards.
• ISO 15189 Certification: Our pathology services are ISO 15189 certified, ensuring rigorous quality management and technical competence.
• Advanced Immunoassay Platforms: We utilize state-of-the-art chemiluminescent immunoassay (CLIA) technology for highly sensitive and precise growth hormone quantification.
• Convenient Online Report Access: Patients can easily view, download, and share their reports via the Chughtai Lab website or mobile app.
• Nationwide Network: With hundreds of collection centers across Pakistan, Chughtai Lab offers unmatched accessibility and convenience.
• Strict Quality Control: We implement rigorous internal quality control protocols and participate in external proficiency testing programs.
• Patient-Focused Care: Our dedicated phlebotomists are specially trained to perform complex dynamic endocrine tests in a comfortable and professional environment.